Skip to main content

Noblegen Biosciences Wins $182K Phase I SBIR Grant from NHGRI

Premium

Noblegen Biosciences has been awarded a $182,000 one-year phase I Small Business Innovation Research grant from the National Human Genome Research Institute to develop its "optipore" sequencing technology, the company disclosed this month.

Noblegen is developing a DNA sequencing platform that combines solid-state nanopores with optical detection. It converts DNA prior to sequencing, replacing each nucleotide with an oligonucleotide, and then hybridizes color-coded molecular beacons to the converted DNA that are stripped off when the molecule runs through a nanopore (IS 6/14/2011).

According to the grant abstract, the company plans to use the funding to develop a synthetic probe library design that will enable cyclical processing and four-color readout of the bases, and to develop and optimize the steps of the circular DNA conversion cycle to prepare the template DNA.

Up until now, the company had been funded through seed funding and government grants to its scientific founder, Amit Meller, an associate professor of biomedical engineering and physics at Boston University.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.